In the fast-paced environment of drug development, pharmaceutical companies need to mine internal and external information quickly and accurately. Many organizations are looking for innovations with NLP (Natural Language Processing), such as large language models, to accelerate drug development. In this webinar, we will discuss how AI (Artificial Intelligence) and NLP are being used at AstraZeneca to facilitate clinical trial design, diversity plans, and health authority advice within regulatory affairs. 

Register now to learn about:

• What is NLP
• NLP for efficacy endpoints and clinical trial design
• NLP to accelerate diversity plans preparation
• NLP implementation into digital platform to mine health authority advice
  

Emilie Louvet
Director Regulatory Data Products at AstraZeneca

Constantinos Katevatis
Associate Director, R&D NLP at IQVIA